Botox and the Breast

December 16, 2016

Botulinum toxin type A plays a role in inhibiting one of the most serious breast surgery complications, capsular contracture. It does so through the TGF-β/Smad signaling pathway, according to a new study.
Researchers treated cultured human fibroblasts in vitro with TGF-β1 and/or botulinum toxin type A. Then they looked at collagen, matris metalloproteinase and Smad expression, according to the abstract.
They found that botulinum toxin type A treatment inhibited Smad 2 phosphorylation and expression of collagen types 1 and 3. But the same treatment enhanced matrix metalloproteinase-2 and matrix metalloproteinase-9. They found that, in vivo, treatment with the neurotoxin reduced capsule thickness and Smad2 phosphorylation in silicone-induced capsules, according to the abstract.
Read more at Cosmetic Surgery Times >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • The Beauty Health Company (SKIN) Rebrands to SkinHealth Systems
    • Amazon Launches GLP-1 Weight Loss Program with One Medical
    • Botox Cosmetic’s “The Confidence Collective” to Empower 250 Women Entrepreneurs
    • Medical Spa Show 2027 Call for Presentations Now Open
    • FDA Warning Letter to Texas Medical Spa Signals Increased Compliance Enforcement